Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab Prophylaxis Prior to Epcoritamab in Non-Hodgkin Lymphoma
NCT06447376Phase 1Recruiting
- Start
- Jan 2025
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of siltuximab in cytokine release syndrome (CRS). Primary endpoint: Incidence of all-grade cytokine release syndrome at 28 days. Started Jan 2025; status: recruiting.
02
Drugs
siltuximab
03
Conditions
cytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT06447376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06447376.